Abstract
Introduction
The International Organization for Standardization's International Standard 15197, Section 7 (ISO 15197:2003) describes an accuracy evaluation for blood glucose monitoring systems (BGMS). 1 The accuracy evaluation described in Section 7 of the standard is a design verification activity to assess the analytical accuracy of the system under controlled conditions in the hands of trained operators. The CONTOUR ® family of products from Bayer HealthCare includes the BGMSs CONTOUR, CONTOUR LINK, CONTOUR USB, and DIDGET ® that all utilize CONTOUR test strips and CONTOUR TS that utilizes CONTOUR TS test strips. Frank and colleagues 2 reported the performance of CONTOUR TS in the hands of lay users and health care professionals. CONTOUR and CONTOUR TS systems are designed to meet the individual needs of various people with diabetes and therefore have different sets of features. For example, the CONTOUR system includes customizable features such as pre-and post-meal markers and a selectable post-meal reminder. CONTOUR and CONTOUR TS BGMSs are over-the-counter devices indicated for the measurement of glucose in whole blood by people with diabetes and by health care professionals.
In this study, the accuracy of the CONTOUR BGMS was assessed in the hands of trained operators according to the analytical performance evaluation outlined in Section 7 of ISO 15197. The goal of this evaluation was to test the performance of the system in the hands of trained operators under optimal operating conditions. Results were expressed using both current ISO 15197:2003 criteria and more stringent criteria.
Methods

The CONTOUR Blood Glucose Monitoring System
Key features of the CONTOUR BGMS that was evaluated in this study are listed in Table 1 . Visual and functional inspections as well as functional testing were conducted on all meters to verify proper functioning prior to the start of the study.
Reference Glucose Measurement
The YSI 2300 Stat Plus Glucose and Lactate Analyzer (YSI Inc., Life Sciences, Yellow Springs, OH) was used as the laboratory reference instrument in the study. The accuracy of the YSI analyzer was validated with a set of serum-based controls that have been assayed by the Bayer analytical laboratory using the reference hexokinase glucose assay developed at the Centers for Disease Control and Prevention (CDC) and recognized by the U.S. Food and Drug Administration (FDA) and the National Reference Systems for Clinical Laboratories. The standard calibration curve for the CDC method was established with glucose solutions made with NIST SRM 917a (dry D-glucose). NIST SRM 965, which is a set of 3 frozen human serum samples with glucose concentrations of approximately 100, 200, and 300 mg/dl, was used as the control in the CDC method. The target values for the SRM 965 controls were established using the NIST definitive glucose method. 
Accuracy Evaluation
Accuracy of the CONTOUR BGMS for fingertip capillary blood testing was assessed at a study site in Mishawaka, Indiana (Bayer HealthCare LLC, Diabetes Care). A total of 105 subjects with diabetes were included in the study (age range, 19-82 years). Twenty-five subjects had type 1 diabetes and 77 had type 2 diabetes (diabetes type was not reported for 3 subjects). An institutional review board approved the study, and all subjects gave their informed consent prior to participation. At the study site, a trained operator tested the subject's fingertip blood with the CONTOUR BGMS and a laboratory reference method (YSI glucose analyzer). Each finger stick sample was tested with three different lots of test strips, with duplicate readings per lot for a total of six readings per sample. Immediately after applying blood to the CONTOUR BGMS, approximately 200 ml of additional blood was collected from the finger into a heparinized microcollection tube for testing in duplicate on the YSI analyzer. ISO 15197:2003 specifies that the glucose concentrations of the finger stick samples shall be distributed as specified in Table 2 . As noted in the standard, a sufficient number of fresh capillary blood samples with very low and very high glucose concentrations may be difficult to obtain from patients.
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To ensure a sufficient number of samples within the specified concentrations, modified blood samples were prepared per the ISO 15197:2003 protocol. Heparinized venous blood was allowed to glycolyze to produce low glucose levels or was supplemented with 20% glucose stock solution to produce high glucose levels (n = 26). Therefore, the total number of blood samples included in the study was 100 (or 74 samples from 105 patients plus the 26 contrived samples). The total number of meter readings was 600 (that is, each sample was tested with 3 test strip lots and 2 tests were conducted per lot for a total of 600 readings 
Results
Of 105 samples obtained from the subjects with diabetes, 74 met the blood glucose concentrations distribution requirements listed in Table 2 . Twenty-six modified blood samples were added to the study for a total of 100 samples per the ISO 15197:2003 protocol. 1 Plasma glucose levels in the test samples ranged from 11 to 554 mg/dl (0.6-30.8 mmol/liter) and hematocrit levels ranged from 26% to 70%. As shown in Table 4) . When grouped according to glucose levels below or above 100 mg/dl, 95.7% of results fell within ±15 mg/dl of the reference value for glucose concentrations below 100 mg/dl and 97.0% of results fell within ±15% of the reference value for glucose concentrations 100 mg/dl or higher ( Table 4) . Both Parkes consensus and Clarke error grid analyses 3, 4 showed that 99.3% (596 of 600) of test results were within zone A, while 0.7% were within zone B, with no results in zones C, D, or E (Tables 5 and  6, Figures 1 and 2) . Table 5 . 1 The criteria apply to "system accuracy evaluations in which users have received proper training, the device has been properly maintained, and required adjustment and control procedures have been followed in accordance with the manufacturer's instructions for use." 1 In other words, the accuracy evaluation described in Section 7 of the standard is a design verification activity intended to assess if the product meets the accuracy specifications set for it. Therefore, calibration errors are not expected to be captured in analytical accuracy studies nor are errors due to other procedural factors such as lack of proper meter maintenance or lack of proper hand washing and drying. Furthermore, studies addressing analytical accuracy are not designed to address successful strategies for self-monitoring of blood glucose or how monitoring data should be used to inform care in individual patients.
Summary of Parkes Consensus Error Grid Analyses of CONTOUR Meter Results
Zone
These concerns are best addressed in Section 8 of ISO 15197:2003, which describes user performance evaluations to demonstrate that users are able to operate the BGMS, given only the instructions and training materials routinely provided with the system and obtain valid glucose results. 1 However, specific accuracy criteria as provided in Section 7 are not provided in Section 8 of the current version of the standard.
Professional organizations and regulatory agencies have proposed a tighter accuracy standard for blood glucose monitoring devices than currently recommended by ISO 15197:2003. [5] [6] [7] Discussions in the health care industry have focused on updating the accuracy requirements for BGMSs with consideration of their intended use. ISO 15197:2003 applies to performance requirements for BGMSs intended for self-monitoring of blood glucose. The FDA currently applies the same accuracy criteria as ISO 15197 for both lay use and health care professional use, but it is possible that different standards will be developed for meters used in hospitals and longterm facilities compared with those indicated for selfmonitoring in the home setting. 6 As guidelines and standards are updated, health care technology will be updated to meet these standards. However, it is also important that patients and health care professionals alike understand all factors that influence accuracy and that education be provided to help ensure that devices are used appropriately for optimal results.
In summary, the current study was conducted in accordance with Section 7 of ISO 15197:2003 and demonstrated that the CONTOUR BGMS exceeds the minimum acceptable accuracy requirements required by ISO 15197:2003. Furthermore, when data were analyzed using more stringent accuracy criteria of results being within ±15 mg/dl (±0.83 mmol/liter) or ±15% of the reference value, 96.7% of results fell within the more stringent criteria. Both Parkes consensus and Clarke error grid analyses showed that 99.3% (596 of 600) of test results were within zone A, while 0.7% were within zone B, indicating that deviations of glucose measurements from reference values had minimal or no effect on clinical action.
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